Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in

Sergey A Shiryaev1, Alexei Y Savinov, Piotr Cieplak

  • 1Inflammatory and Infectious Disease Center, Burnham Institute for Medical Research, La Jolla, California, United States of America.

Plos One
|March 21, 2009
PubMed
Abstract

Insights

Matrix metalloproteinase 6 (MT6-MMP) is highly effective at cleaving myelin basic protein (MBP) isoforms, generating an immunogenic peptide that stimulates T cells. This finding suggests MT6-MMP is a promising drug target for multiple sclerosis (MS).

Area of Science:

  • Neuroimmunology
  • Enzymology
  • Proteomics

Background:

  • Matrix metalloproteinases (MMPs) contribute to demyelination in multiple sclerosis (MS) by fragmenting myelin basic protein (MBP).
  • The specific MMPs involved in MBP cleavage and their relative contributions remain unclear.
  • MBP splice variants (BG21, J37) are expressed in neurons and immune cells, suggesting broader roles.

Purpose of the Study:

  • To identify the primary matrix metalloproteinase responsible for cleaving myelin basic protein (MBP) and its splice variants.
  • To investigate the immunogenic potential of MBP fragments generated by specific MMPs.
  • To evaluate MT6-MMP as a potential therapeutic target for MS.

Main Methods:

  • In vitro cleavage assays using various MMPs (MMP-2, -8, -9, -10, -12, MT1-MMP to MT6-MMP) against MBP, BG21, and J37 isoforms.
  • Mass spectrometry analysis to identify cleavage sites and fragment sequences.
  • Mixed lymphocyte culture assay to assess T cell proliferation stimulated by MMP-generated MBP peptides.

Main Results:

  • MBP, BG21, and J37 isoforms are susceptible to proteolysis by multiple MMPs.
  • MT6-MMP demonstrated superior efficiency in cleaving MBP isoforms compared to other tested MMPs.
  • MT6-MMP proteolysis generated the N-terminal 1-15 MBP peptide, which selectively stimulated the proliferation of EAE-specific T cell clones.

Conclusions:

  • MT6-MMP plays a significant role in cleaving MBP isoforms, producing an immunogenic peptide implicated in MS pathology.
  • MT6-MMP, activated by furin and localized in lipid rafts, is a promising novel drug target for MS.
  • Understanding MT6-MMP's function offers new therapeutic avenues for autoimmune demyelinating diseases.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...